Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL

Summary

This study employs a 1:1 randomization of patients to receive romidepsin alone verses romidepsin plus pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The primary objectives will be to identify a 75% improvement in progression free survival (PFS) among patients receiving the combination compared to single agent romidepsin.

Timeline

Start

2018-09-01

Primary completion

2018-11-01

Completion

2018-11-01

Drugs

Indications